Sanofi (EPA:SAN) received a €95.00 ($110.47) target price from equities researchers at Jefferies Financial Group in a report released on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 10.09% from the stock’s previous close.
Several other equities research analysts also recently weighed in on the company. Barclays set a €75.00 ($87.21) price objective on Sanofi and gave the company a “sell” rating in a report on Friday. Credit Suisse Group set a €94.00 ($109.30) target price on Sanofi and gave the stock a “buy” rating in a report on Friday, November 1st. UBS Group set a €89.50 ($104.07) target price on Sanofi and gave the company a “buy” rating in a research report on Tuesday. Bank of America set a €100.00 ($116.28) price target on Sanofi and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Kepler Capital Markets set a €88.00 ($102.33) price target on Sanofi and gave the stock a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of €89.81 ($104.43).
Shares of EPA:SAN opened at €86.29 ($100.34) on Tuesday. The company has a fifty day moving average of €83.29 and a 200-day moving average of €78.94. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Capital Gains
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.